Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.

Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.

The patient was highly symptomatic despite the stable vision. Goldberg said a key takeaway for attendees was that “visual ...

Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted ...

Technician-led screening catches hidden ocular surface disease before cataract surgery and helps decide when to delay surgery ...

Murtaza K. Adam, MD, reviews 3 patient cases to explore referral patterns, neovascularization after treatment, and barriers to care.

October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care. October was a month of meetings ...

Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's ...

Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.